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Abstract: Friedreich ataxia (FRDA) is the most common autosomal recessive ataxia. Oxidative 
damage within the mitochondria seems to have a key role in the disease phenotype. Therefore, 
FRDA treatment options have been mostly directed at antioxidant protection against mitochon-
drial damage. Available evidence seems to suggest that patients with FRDA should be treated 
with idebenone, because it is well tolerated and may reduce cardiac hypertrophy and, at higher 
doses, also improve neurological function, but large controlled clinical trials are still needed. 
Alternatively, gene-based strategies for the treatment of FRDA may involve the development of 
small-molecules increasing frataxin gene transcription. Animal and human studies are strongly 
needed to assess whether any of the potential new treatment strategies, such as iron-chelating 
therapies or treatment with erythropoietin or histone deacetylase inhibitors and other gene-based 
strategies, may translate into an effective therapy for this devastating disorder. In this review, 
we try to provide an answer to some questions related to current and emerging treatment options 
in the management of FRDA.
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Introduction
Friedreich ataxia (FRDA, OMIM #229300) is the most common autosomal reces-
sive ataxia among Caucasian population, and it is caused by mutations in the FXN 
gene (OMIM *606829), mainly an expanded GAA triplet repeat in the intron 1.1 Age 
at onset is typically 5–25 years. Sensory neurons in the dorsal root ganglia are lost 
initially, with secondary degeneration of the spinocerebellar tract, pyramidal tract, 
and dorsal columns.2 FRDA is, therefore, characterized by progressive gait and limb 
ataxia,   dysarthria, loss of vibration and proprioceptive sense, areflexia, abnormal eye 
movements, and pyramidal signs. Involvement of the auditory sensory neurons and 
pathways may also be found, as in optic atrophy.3 Ataxia of mixed cerebellar and 
sensory type is the cardinal symptom. The first symptom is usually gait instability, 
though scoliosis may already be present when neurologic symptoms appear, and, in 
rare cases, hypertrophic cardiomyopathy is diagnosed before the onset of ataxia.
In patients with FRDA, voxel-based morphometry showed a symmetrical volume 
loss in dorsal medulla, infero-medial portions of the cerebellar hemispheres, the ros-
tral vermis, and in the dentate region.4 No volume loss in cerebral hemispheres was 
observed. The atrophy of the cerebellum and medulla correlated with the severity of 
the clinical deficit and disease duration.4 Moreover, some magnetic resonance imaging-
based studies found cerebral white matter atrophy or dysfunction.5,6Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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A possible manifestation of this disease is hypertrophic 
cardiomyopathy, described in up to two-third of patients with 
FRDA.7 Ventricular arrhythmias can also occur. Later in the 
course of the disease, the hypertrophied heart can develop 
systolic dysfunction and heart failure and arrhythmias are 
possible causes of death in these patients.8 Diabetes, scoliosis, 
and pes cavus are other possible manifestations of FRDA. 
Clinical course is variable, but on average 10–15 years after 
onset, patients lose the ability to walk, stand, and sit without 
support.3 Age at diagnosis, which may incorporate other 
genetic and environmental factors, may be more important 
than GAA length in predicting cardiomyopathy, scoliosis, 
and disease progression.9
In FRDA the genetic abnormality results in the defi-
ciency of frataxin, a protein targeted to the mitochondrion.10 
In about 98% of patients, the disease is caused by a triplet 
GAA expansion within the first intron of the frataxin gene on 
chromosome 9q13, which impedes transcription of the gene 
and limits protein production.1,11 The repeat expansions can 
range from 70 to 90 repeats (normal less than 40) to over 
1,000, with inverse correlation of age at onset, severity of the 
disease, and associated systemic symptoms.2 Heterozygous 
carriers are clinically healthy. FRDA is the most common 
disease-causing triplet-repeat expansion identified so far, 
about 1 in 100 Europeans being a carrier. No other disease 
has been recognized to date to be caused by an expansion of 
GAA triplets.3 Some patients are compound heterozygotes 
with the GAA expansion in one allele and one of a variety 
of point mutations in the other allele.2 The FRDA-associated 
expansion shows instability when transmitted from parent 
to child. Expansions and contractions can both be observed 
and are equally likely after maternal transmission, whereas 
contractions are most common after paternal transmission.3 
In this regard, FRDA resembles the other diseases associated 
with very large expansions in noncoding regions, including 
fragile X syndrome and myotonic dystrophy, and differs from 
the diseases that are caused by CAG repeats in coding regions, 
such as dominant ataxias and Huntington disease, in which 
size increases typically occur after paternal transmission.3
FRDA pathogenetic theories  
and their relevance for  
therapeutic approaches
Although the exact physiological function of frataxin is not 
known, its involvement in iron–sulfur cluster biogenesis has 
been suggested.12 Frataxin iron-binding capacity is quite 
robust. Even when 5 of the most conserved residues from the 
putative iron-binding region are altered, at least 2 iron atoms 
per monomer can be bound.13 Current evidence suggests 
that loss of frataxin impairs mitochondrial iron handling14 
and respiratory chain function and contributes to increased 
oxidative stress and cellular damage.2
In a conditional knockout mouse model where frataxin was 
removed from the heart, transferrin receptor-1 was upregulated, 
resulting in increased iron uptake from   transferrin.15 There is 
also marked downregulation of ferritin that is required for 
iron storage and decreased expression of the iron exporter, 
ferroportin 1, leading to decreased cellular iron efflux. The 
increased mitochondrial iron uptake is facilitated by upregu-
lation of the mitochondrial iron transporter,   mitoferrin 2.15 
This stimulation of iron uptake probably attempts to rescue 
the deficit in mitochondrial iron metabolism that is due to 
downregulation of mitochondrial iron utilization (heme and 
iron–sulfur cluster synthesis and iron storage in mitochondrial 
ferritin). Therefore, increased mitochondrial iron uptake 
coupled with decreased utilization and release leads to mito-
chondrial iron-loading.16
Abnormalities of the neuronal cytoskeleton due to   oxidative 
stress and increased protein glutathionylation have been also 
suggested to have a potential role in FRDA.17 Oxidative damage 
within the mitochondria seems to have a key role in the disease 
phenotype.18 A combined deficiency of a Krebs-cycle enzyme, 
aconitase, and 3 mitochondrial   respiratory-chain complexes 
was reported in endomyocardial biopsy samples from patients 
with this disorder.19 All 4 enzymes share iron – sulfur cluster-
containing proteins that are damaged by iron overload through 
generation of   oxygen free radicals.19 Using phosphorus 
magnetic resonance spectroscopy, Lodi et al20   demonstrated 
a maximum rate of muscle mitochondrial adenosine triphos-
phate (ATP) production below the normal range in all the 
12 studied FRDA patients and a strong negative correlation 
between mitochondrial ATP production and the number of 
GAA repeats in the smaller allele, suggesting that FRDA 
is a nuclear-encoded mitochondrial disorder.20 Moreover, 
Giacchetti et al21 reported an influence of the mitochondrial 
DNA polymorphisms on the FRDA phenotype. These authors 
studied 99 patients with FRDA and 48 control individuals, 
all from southern Italy. They found that patients belonging to 
the haplogroup U class had a delay of 5 years in the disease 
onset and a lower rate of   cardiomyopathy.21 Mitochondrial 
DNA polymerase (POLG) CAG repeat instability has been 
also proposed as a predisposing factor that, in combination 
with environmental risk factors, may affect age of onset 
and FRDA progression.22 For the described reasons, FRDA 
treatment options have been mostly directed at   antioxidant 
protection against   mitochondrial   damage.   Interestingly, Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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other studies   demonstrated that in FRDA   mitochondrial iron 
accumulation did not induce oxidative stress and that FRDA 
is a neurodegenerative disease not associated with oxidative 
damage.23
To date, no randomized controlled trial using antioxidants 
or any other pharmacological treatment has shown signifi-
cant benefit on neurological symptoms associated FRDA.24 
Moreover, the design of clinical trials in FRDA presents 
some problems, such as the lack of reliable biomarkers 
that correlate with clinical dysfunction and the rarity of 
the condition. Therefore, therapeutic strategies are still 
unclear. In this review, we try to provide an answer to some 
  questions related to current and emerging treatment options 
in the management of FRDA. References for this review 
were identified by searches of PubMed until May 2010 
with the term “Friedreich*”; articles especially considering 
potential therapeutic approaches were considered. Emphasis 
was placed on comprehensive reviews and original articles 
published after 1998. Other articles were identified through 
references from relevant articles. Only papers published in 
English were reviewed.
Which pharmacological agents 
were effective in FRDA cellular  
and animal models?
PPARγ agonists
A recent microarray analysis of heart and skeletal muscle in 
a mouse model of frataxin deficiency showed molecular evi-
dence of increased lipogenesis in skeletal muscle, and altera-
tion of fiber-type composition in heart, consistent with insulin 
resistance and cardiomyopathy, respectively.25 Since the 
peroxisome proliferator-activated receptor gamma (PPARγ) 
pathway is known to regulate both processes, dysregulation 
of this pathway may play a role in FRDA. PPARγ coactiva-
tor 1-alpha (PGC-1a) downregulation may contribute to the 
blunted antioxidant response observed in cells from FRDA 
patients.26 PGC-1a is a transcriptional master regulator of 
mitochondrial biogenesis and antioxidant responses, and can 
be restored by agonist pioglitazione in FRDA cells,26 suggest-
ing a potential therapeutic approach for FRDA. Moreover, 
Marmolino et al27 investigated the effect of another PPARγ 
agonist (Azelaoyl PAF) on the frataxin protein and mRNA 
expression profile in human neuroblastoma cells (SKNBE) 
and primary fibroblasts from skin biopsies from FRDA 
patients and healthy controls. Azelaoyl PAF increased both 
messenger RNA and protein levels of intracellular frataxin 
in SKNBE cells and fibroblasts from FRDA patients.27
iron chelators
Iron chelators that target the mitochondrion have been pro-
posed (ie, deferiprone).28,29 Adding the chelator deferiprone 
at clinical concentrations to inducibly frataxin-deficient 
HEK-293 cells resulted in chelation of mitochondrial labile 
iron, involved in oxidative stress.30 This led to restoration 
of impaired mitochondrial membrane and redox potentials, 
increased ATP production and oxygen consumption, and 
attenuation of mitochondrial DNA damage and reversal of 
hypersensitivity to apoptosis.30 On the other hand, a direct 
consequence of chelating mitochondrial free iron in various 
cell systems is a concentration and time-dependent loss of 
aconitase activity, which was shown to precede decreased 
cell proliferation.31 Therefore, if chelating excessive mito-
chondrial iron may be beneficial at some stage of the disease, 
attention should be paid to not fully deplete mitochondrial 
iron store.31 Li et al32 investigated the regulation of frataxin 
expression by iron and reported that frataxin mRNA levels 
decreased significantly in multiple human cell lines treated 
with the iron chelator desferal. In addition, frataxin mRNA 
and protein levels decreased in fibroblast and lymphoblast 
cells derived from both normal controls and from patients 
with FRDA.32 Lymphoblasts and fibroblasts of FRDA 
patients show evidence of cytosolic iron depletion, which 
may occur as frataxin-deficient cells overload their mito-
chondria with iron,32 as already discussed. Therapeutic efforts 
should focus on an approach that combines iron removal from 
mitochondria with a treatment that increases cytosolic iron 
levels to maximize residual frataxin expression in FRDA 
patients.32
Antioxidant agents
Coenzyme Q10 has been widely used for the treatment of 
neurodegenerative disorders, as well as its analog idebenone, 
which shares an identical modified parahydroxybenzo-
ate ring with Coenzyme Q10, but has a short carbon tail. 
  Idebenone was cytoprotective in fibroblasts from patients 
with FRDA.33 Because of the role of mitochondrial oxidative 
damage in FRDA, Jauslin et al34 compared the efficacy of 
mitochondria-targeted and untargeted antioxidants derived 
from coenzyme Q10 and from vitamin E at preventing oxi-
dative stress-induced cell death in cultured fibroblasts from 
FRDA patients in which glutathione synthesis was blocked. 
Ubiquinones have been shown to protect mitochondria from 
oxidative damage, but only a small proportion of externally 
administered ubiquinone is taken up by mitochondria.35 
Conjugation of the lipophilic triphenylphosphonium cation 
to a ubiquinone moiety has produced a compound, MitoQ, Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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which accumulates selectively into mitochondria. MitoQ 
passes easily through all biological membranes and, because 
of its positive charge, is accumulated several 100-fold 
within   mitochondria driven by the mitochondrial membrane 
potential.35 The mitochondria-targeted antioxidant MitoQ 
was 800-fold more potent than the untargeted analog ide-
benone.34 The mitochondria-targeted antioxidant MitoVit E 
was 350-fold more potent than the water soluble analog.34 
Therefore, targeted antioxidants may have therapeutic poten-
tial in FRDA and in other disorders involving mitochondrial 
oxidative damage, but have not been investigated in FRDA 
patients to date.
A dose-escalation trial found that idebenone was effi-
cacious in a frataxin-deficient mouse model of FRDA.36 
Low-dose idebenone (10 and 30 mg/kg per day) showed no 
benefit, whereas high-dose idebenone (90 mg/kg per day) 
delayed the cardiac disease onset, progression, and death of 
frataxin-deficient animals by 1 week.36
Gene-based strategies
FRDA is a loss of function disorder, therefore gene-based 
strategies designed to increase frataxin levels could be an 
ideal therapy for this disease, although there are still tech-
nological limitations to their clinical applicability.37 Viral 
vectors expressing frataxin partially corrected sensitivity to 
oxidative stress in FRDA fibroblasts.38,39 Furthermore, in mice 
with a localized frataxin reduction in the brainstem functional 
impairment could be corrected by exposure to HSV-1 vector 
expressing frataxin cDNA.40 Other studies reported that com-
pounds specifically targeting the GAA repeat, such as DNA 
sequence-specific polyamides41 or pentamidine,42 were capable 
of increasing frataxin transcription. The exact mechanism by 
which these DNA-binding compounds increase transcription 
through GAA repeats still needs further characterization.37
HDAC inhibitors
Alternative gene-based strategy for the treatment of FRDA 
would involve the development of small-molecules increas-
ing frataxin gene transcription.37 Expanded GAA repeats 
may silence frataxin expression inducing heterochromatin 
formation, and/or forming non B-DNA structures, such as 
triplex and sticky DNA, which block gene transcription. 
Therefore, possible treatments for FRDA may include drugs 
that facilitate chromatin opening, such as histone deacetylase 
(HDAC) inhibitors.37 Gene silencing at expanded FXN alleles 
is accompanied by hypoacetylation of histones H3 and H4 and 
trimethylation of histone H3, observations that are consistent 
with a heterochromatin-mediated repression mechanism.43 
Herman et al43 reported the synthesis and characterization of 
a class of HDAC inhibitors that reversed FXN silencing in 
primary lymphocytes from individuals with FRDA. These 
molecules directly affected the histones associated with FXN, 
increasing acetylation at particular lysine residues on histones 
H3 and H4. One compound, BML-210, showed a significant 
increase in frataxin message levels by approximately 2-fold.43 
Butyric acid is another HDAC inhibitor reported to increase 
frataxin expression.44 Furthermore, compounds with pimelic 
diphenylamide basic structure were able to upregulate frataxin 
in cells from FRDA patients and in a mouse model.45 HDAC3 
could be the likely cellular target of the pimelic diphenyl-
amides HDAC inhibitors and the target for therapeutic 
intervention in FRDA.46 Although both the HDAC3 and 
HDAC1/2-specific compounds share a similar mechanism 
of inhibition of their target enzymes, only HDAC3-specific 
compounds increase frataxin gene expression and frataxin 
protein in cells.46 Rai et al47 treated KIKI mice (homozygous 
mice carrying a [GAA]230 repeat in the first intron of the mouse 
frataxin gene) with a novel HDAC inhibitor, compound 106, 
which substantially increases frataxin mRNA levels in cells 
from FRDA individuals. The treatment increased histone 
H3 and H4 acetylation in chromatin near the GAA repeat 
and restored wild-type frataxin levels in the nervous system 
and heart, as determined by quantitative reverse transcription 
polymerase chain reaction and semiquantitative western blot 
analysis.47 Lack of acute toxicity, normalization of frataxin 
levels, and of the transcription profile changes resulting from 
frataxin deficiency may provide support to a possible efficacy 
of this or related compounds in FRDA patients.47
Conclusive remarks
In conclusion, gene-based strategies (including HDAC inhibi-
tors), the agonist pioglitazione, iron chelators that target the 
mitochondrion such as deferiprone, coenzyme Q10, vitamin E 
(especially their mitochondria-targeted forms), and idebenone 
were found to be effective in FRDA cellular and animal 
  models. Clinical studies with some of these agents are reviewed 
in the next paragraphs. Moreover, there is some preliminary 
evidence that flavin adenine dinucleotide48 and hemin44 may 
rescue the phenotype of frataxin deficiency in cellular and 
animal models, but further studies are still needed.
Is there a role for idebenone and 
other antioxidants in FRDA patients?
idebenone
The antioxidant idebenone is a short-chain benzoquinone 
derivative with a structure similar to coenzyme Q10 but with Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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a more favorable pharmacokinetic profile.49 In vitro studies 
have shown that it acts both as an antioxidant, preventing 
damage to the mitochondrial membrane, and as an electron 
carrier, supporting mitochondrial function and ATP produc-
tion.50 High doses of idebenone are safe and well tolerated in 
patients with FRDA.49 The idebenone half-life was relatively 
consistent across dose levels (2.6–21.7 hours).49 It exhib-
ited dose-dependent pharmacokinetics in daily doses up to 
2,250 mg.51 Idebenone plasma levels are thought to correlate 
with central nervous system concentrations because of its 
ability to penetrate central nervous system.49
Schulz et al52 measured concentrations of 8-hydroxy-
2′-deoxyguanosine (8OH2′dG), a marker of oxidative DNA 
damage, in urine and of dihydroxybenzoic acid (DHBA), 
a marker of hydroxyl radical attack, in plasma of 33 patients 
with FRDA. They found a 2.6-fold increase in normal-
ized urinary 8OH2′dG but no change in plasma DHBA as 
compared with controls. Oral treatment with 5 mg/kg/day 
of idebenone for 8 weeks significantly decreased urinary 
8OH2′dG concentrations.52
Idebenone is a promising drug for treatment of FRDA.53 
Early trials have demonstrated that low-dose idebenone 
(5 mg/kg per day) reduced cardiac hypertrophy (as deter-
mined by echocardiography)54,55 in the majority of patients 
with FRDA, with no influence upon clinical progression of 
the neurological disease.54,56
Recently, a randomized, placebo-controlled trial has 
been conducted on 48 patients with genetically confirmed 
FRDA.57 Treatment with higher doses of idebenone (up to 
45 mg/kg) was generally well tolerated and associated with 
improvement also in neurological function and activities of 
daily living in patients with FRDA. The degree of improve-
ment correlated with the dose of idebenone, suggesting that 
higher doses may be necessary to have a beneficial effect on 
neurological function.57 It has been also suggested that the 
disease stage and patient age at which idebenone treatment is 
initiated may be important factors in the effectiveness of the 
therapy.58,59 Larger randomized trial focusing on the response 
to idebenone therapy of both neurological and heart symp-
toms are required to confirm whether an early diagnosis of 
FRDA can be exploited to initiate such antioxidant treatment 
in order to prevent the progression of this disorder.
Other antioxidants
To evaluate the long-term efficacy of a combined antioxidant 
and mitochondrial enhancement therapy on the bioenergetics 
and clinical course of 10 patients with FRDA, Hart et al60 
  performed an open-labeled pilot trial over 47 months with 
a combined coenzyme Q10 (400 mg/d) and vitamin E 
(2,100 IU/d) therapy. They reported a significant improvement 
in cardiac and skeletal muscle mitochondrial bioenergetics as 
assessed using phosphorus magnetic resonance spectroscopy, 
and heart function assessed by echocardiographic fraction 
shortening significantly improved. Although improved fraction 
shortening was reported, there was no impact upon the degree 
of cardiac hypertrophy evident before therapy was started.60 
These results must be interpreted with caution because of 
limited patient numbers and the absence of a placebo group.
Another pilot study investigated the potential for high-
dose CoQ10/vitamin E therapy to modify clinical progres-
sion in FRDA.61 Fifty patients were randomly divided into 
high-dose or low-dose CoQ10/vitamin E groups. At base-
line, serum CoQ10 and vitamin E levels were significantly 
decreased in patients.61 During the trial, CoQ10 and vitamin 
E levels significantly increased in both groups. Serum CoQ10 
level resulted to be the best predictor of a positive clinical 
response to CoQ10/vitamin E therapy.61
Conclusive remarks
Overall, because of the lack of controlled studies, the vari-
able doses used and the association with other antioxidant 
medications, vitamin E has not been appropriately tested in 
FRDA, and no conclusions can yet be drawn about its safety 
and efficacy in this disorder.62 More research is needed to 
identify the role of vitamin E, and of other antioxidant 
agents, if any, in the management of FRDA and other neu-
rodegenerative disorders.63 A meta-analysis (which included 
68 randomized trials with 232,606 healthy participants and 
patients with various diseases) reported that treatment with 
β-carotene, vitamin A, and vitamin E may increase all-cause 
mortality.64 Further study of causes of mortality is needed. 
These findings contradicts observational studies, claiming 
that synthetic antioxidant supplements improve health.64 
Therefore, more research is needed to establish the real safety 
of such compounds, including vitamin E.63
In conclusion, available evidence (Table 1) seems to sug-
gest that patients with FRDA should be treated with idebenone, 
because it is well tolerated and may reduce cardiac hypertrophy 
and, at higher doses (up to 45 mg/kg), also improve neurological 
function, but large controlled clinical trials are still needed.
Other pharmacological agents 
could be useful in FRDA patients?
Carnitine and creatine
L-carnitine and creatine are natural compounds that may 
enhance cellular energy transduction.63 A placebo-controlled Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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triple-phase crossover trial of L-carnitine (3 g/d) and creatine 
(6.75 g/d) has been performed in 16 patients with genetically 
confirmed FRDA.65 Ataxia rating scale and echocardio-
graphic parameters remained unchanged.65
erythropoietin
Peripherally administered erythropoietin (EPO), which could 
increase the amount of frataxin protein at posttranslational 
level in primary fibroblast cell cultures66 or isolated lympho-
cytes67 derived from FRDA patients, crosses the blood – brain 
  barrier.68 It may stimulate neurogenesis, neuronal differ-
entiation, and activate brain neurotrophic, antiapoptotic, 
antioxidant, and anti-inflammatory signaling.68 Boesch 
et al69 performed an open-label clinical pilot study with 
recombinant human EPO. Twelve FRDA patients received 
5,000 units recombinant human EPO 3 times weekly subcu-
taneously. Treatment with recombinant human EPO showed 
a persistent and significant increase in frataxin levels after 
8 weeks and a reduction of oxidative stress markers (urinary 
8-hydroxydeoxyguanosine and serum peroxides).69 The 
same research group70 subsequently reported a 6-month 
open-label clinical pilot study of safety and efficacy of EPO 
treatment in 8 FRDA patients (2,000 units thrice a week). 
Scores in Ataxia Rating Scales improved significantly, 
with a persistent increase of frataxin levels and a reduction 
of oxidative stress parameters, but increases in hematocrit 
requiring phlebotomies occurred in 4 of 8 patients. Safety 
monitoring with regular blood cell counts and parameters 
of iron metabolism is a potential   limitation of this approach, 
which to date has not been evaluated with a double-blind 
controlled study.70
Conclusive remarks
To date, pharmacological approaches other than idebenone 
and symptomatic therapies are not routinely indicated in 
patients with FRDA.
Which symptomatic 
countermeasures are available  
for FRDA patients?
Symptomatic therapy, which comprises antidiabetic therapy 
in case of diabetes and cardiologic therapy in case of 
rhythm abnormalities or heart failure,71 as well as baclofen 
for spasticity,72 may markedly improve quality of life and 
prognosis of affected individuals. The levorotatory form 
of 5-hydroxytryptophan could be able to modify the cer-
ebellar symptoms in patients with FRDA, but the effect is 
only   partial and not clinically major.73 Recent preliminary Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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evidence   suggests that riluzole may be potentially   effective 
as   symptomatic therapy in diverse forms of cerebellar 
ataxia.74
Furthermore, in patients with cerebellar ataxia, coordi-
native training improved motor performance and reduced 
ataxia symptoms, enabling them to achieve personally 
meaningful goals in everyday life.75 Rehabilitation therapies 
usually focus on strategies and compensatory techniques for 
maintaining or improving abilities to continue to participate 
in all environmental contexts for as long as possible.76 The 
benefits of physical exercise programs have been demon-
strated for patient with other degenerative disabilities that 
include ataxia, but at present there is little evidence sup-
porting specific physical therapy interventions that would 
address impairments or functional concerns in patients with 
FRDA.76 Patients with FRDA may improve aerobic fitness 
by participating in stationary cycling for 20–25 minutes at 
70%–85% of their maximum heart rate.77 The plan of care 
should include daily attention to range of motion, including 
muscle length and soft-tissue extensibility, as well as main-
taining independence in mobility.77
Maintaining biomechanical alignment is another impor-
tant therapeutic consideration.76 Orthopedic problems such as 
foot deformities and scoliosis are often treated with orthoses78 
or surgery79 and may result in a temporary improvement in 
function.76 Early intervention for biomechanical changes in 
the foot significantly improves alignment and thus weight 
bearing ability and mobility outcomes.79
Conclusion and perspectives
In conclusion, to date the best care for patients with FRDA 
has not been defined according to evidence-based criteria, 
and all efforts should be made to obtain solid standards 
of care, although this goal is difficult to accomplish for 
a rare disease.80 The first phase 2 trial of idebenone has 
shown dose-dependent effects on neurological scale scores 
in children and adolescents with FRDA.57 Large trials are 
needed to investigate whether all patients with FRDA can 
benefit from idebenone treatment, regardless of age and 
disease stage.80
Additional studies with animal models will be essential 
for an enhanced understanding of the disease pathophysiol-
ogy and for the development of better therapies.81 Animal 
and human studies are strongly needed to assess if any of the 
described new treatment strategies, such as iron-chelating 
therapies or treatment with EPO or HDAC inhibitors and 
other gene-based strategies, may translate into an effective 
therapy for this devastating disorder.
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